Panel: A Case-based Approach to the Management of Bladder Cancer

Similar documents
Point-Counterpoint: Radiation & Bladder Cancer

Bladder Cancer Guidelines

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

3.1 Investigations for Patients Presenting with Haematuria Table 1

Case 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be:

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

A patient with recurrent bladder cancer presents with the following history:

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

MEDitorial March Bladder Cancer

When to Integrate Surgery for Metatstatic Urothelial Cancers

BLADDER CANCER: PATIENT INFORMATION

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC

Bladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope


Issues in the Management of High Risk Superficial Bladder Cancer

Lymph node dissection: how much is enough?

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor

Case by Case: Critical Issues in Superficial Bladder Cancer Management 5/24/05 13:46 1

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

Neoplasms of the Prostate and Bladder

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Management of Superficial Bladder Cancer Douglas S. Scherr, M.D.

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

Optimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC

Carcinoma of the Urinary Bladder Histopathology

Bladder Case # 1. Principal Diagnosis: Bladder Tumor, Suspect Transitional Cell Carcinoma. Secondary Diagnoses: 1. Hypertension. 2. Hyperlipidemia.

Invasive Bladder Transitional Cell Carcinoma OBJECTIVES

Renal tumors of adults

Bladder Cancer. Clinical Case Conference

Bladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist

INTRAVESICAL THERAPY AND FOLLOW-UP OF SUPERFICIAL TRANSITIONAL CELL CARCINOMA OF THE BLADDER

Management options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center

Early radical cystectomy in NMIBC Marko Babjuk

10/23/2012 CASE STUDIES: RENAL AND UROLOGIC IMPAIRMENTS. 1) Are there any clues from this history that suggest a particular diagnosis?

Pathology Driving Decisions

Staging and Grading Last Updated Friday, 14 November 2008

H(a)ematuria. FX Keeley Consultant Urologist Bristol Urological Institute

Hey Doc, there s blood in my urine Evaluation of hematuria. Christian S. Kuhr, MD FACS May 4, 2018

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER

ICUD 2011 Recommendations. Bladder Cancer


Trimodality Therapy for Muscle Invasive Bladder Cancer

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre

Urological Tumours 1 Kidney tumours 2 Bladder tumours

Bladder tumour resection (TURBT): procedure-specific information

Chemotherapy Treatment Algorithms for Urology Cancer

Open Radical Cystectomy Tips and Tricks in Males and Females

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008

SUPERFICIAL BLADDER CANCER MANAGEMENT

Collection of Recorded Radiotherapy Seminars

Bladder Tumours Urology Patient Information Leaflet

UNDERSTANDING BLADDER CANCER

URETHRAL CANCER EPIDEMIOLOGY - 1

Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer

UICC TNM 8 th Edition Errata

Organ-sparing treatment of invasive transitional cell bladder carcinoma

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

Highlighting Clinical Trials Muscle Invasive Bladder Cancer

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI

Guidelines for the Management of Bladder Cancer

Upper Tract Tcc. Mohan Arianayagam FRACS (Urology)

Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature. William Julian, MD. James J.

Attachment #2 Overview of Follow-up

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis?

Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

Attachment #2 Overview of Follow-up

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

Advanced Pathophysiology Unit 7: Renal-Urologic Page 1 of 6

Urinary Bladder Cancer

Partial Cystectomy for Invasive Bladder Cancer

Pancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)

Bladder Cancer Basics For the Newly Diagnosed

RATIONALE: The organs making up the urinary system consist of the kidneys, bladder, urethra, and ureters.

CUA guidelines on the management of non-muscle invasive bladder cancer

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer

September 10, Dear Dr. Clark,

Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl

Pancreatic Cancer. BIOLOGY: Not well defined (genetic and enviromental factors) CLINICAL PRESENTATION: Abd pain, jaundice, weight loss.

Uroradiology For Medical Students

Bladder Sparing Treatment of Muscle Invasive Bladder Cancer

Five Views of Transitional Cell Carcinoma: One Man s Journey

Update on bladder cancer diagnosis and management

Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic

Mayo Clinic Update in Urology 2017: February 20-24, 2017 Atlantis, Paradise Island Bahamas

Appendix 4 Urology Care Pathways

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.

Intravesical BCG clinical care pathway

Radical Cystectomy Often Too Late? Yes, But...

Intravesical Therapy for Bladder Cancer

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Care of bladder cancer patients diagnosed in Northern Ireland 2010 & 2011 (Summary)

Endovascular Repair o Abdominal. Aortic Aneurysms. Cesar E. Mendoza, M.D. Jackson Memorial Hospital Miami, Florida

Trans Urethral Resection of Bladder Tumour (TURBT) Department of Urology Information for Patients

Transcription:

Panel: A Case-based Approach to the Management of Bladder Cancer ~ Moderator: Robert Donohue, MD Panel: David C. Beyer, MD E. David Crawford, MD Donald L. Lamm, MD Paul D. Maroni, MD TCC Cases Robert E. Donohue M.D. Denver VAMC University of Colorado Bladder cases ChRx immediately post-op second look BCG instillation induction and maintenance N+, LE+, fever, restart, Drug Eluting Stents diverticulum T2 1] retrbt 2] bch Rx 3] Cystectomy 4] Bladder preservation 5] neo-adjivant Ch Rx + cystecytomy Bladder cases #1 65 - gross hematuria CT extensive tumor 1 st TURBT incomplete TURBT resected 50%; slides 1 / Ta 2 nd TURBT resect remainder only small amʼt; slides 1 / Ta 3 rd TURBT second look, slides; negative for tumor PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona 6.1

transitional cell Ca Bladder cases #1 65 - gross hematuria CT extensive tumor 1 st TURBT incomplete TURBT resected 50%; slides 1 / Ta 2 nd TURBT resect remainder only small amʼt; slides 1 / Ta 3 rd TURBT second look, slides; negative for tumor J.U. 162: 24, 1999 6.2 PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona

Bladder cases #1 65 - gross hematuria instillational chemotherapy after each resection? second look? q 3 or 6 month follow-up? JU 178: 1201, 2007 PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona 6.3

Bladder case #1 increase time interval of cystos, reduce or eliminate ambulatory TURBT procedures, do office fulgurations, < five tumors; < 0.5 cms, size Herr Bladder cases #2 77 gross hematuria for two months, 2007 2007 1 / Ta, M. propria negative 2009 1 / Ta 2009 2 / T1, M. propria, negative Grade 1, Ta TCC Bladder cases #2 TURBT 3 recurrent tumors immediate ChRx instillation When to start BCG induction dose, frequency, duration, second course, 3 or 6 weeks? maintenance? 1 year, 3 years, 7 years 6.4 PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona

Bladder cases #2 TURBT 3 recurrent tumors 3 instillations of BCG with induction; week 4 - UA nitrite +, Leuk esterase +, 50 WBCs/ hpf UTI? c/s sent; negative, serial urinalyses; Leuk esterase +, w5 >50 WBCs, >20 WBCs,> 20 WBCs 3 week hiatus? What to do? Bladder cases #3 64 microscopic hematuria recurrent tumor, 2 / Ta maintenance chemotherapy 7 year plan 3 week therapy every six months; cystoscopy and cytology q 3 mths instillation Tuesday; 104* fever Friday, Sat, Sun Bladder cases #3 64 microscopic hematuria instillation Tuesday; NB c-i-c, warned about fever above 100* 104* fever Friday, Sat, Sun, Monday, E.R. R3 sees patient; only test I wanted was urine c/s BCG, Gram neg or Enterococcus only test not done but ordered Bladder cases #3 64 microscopic hematuria 3 or 6 months of anti-tuberculous therapy? restart BCG, normal dose? 1/100 dose? switch to alpha-interferon? switch to BCG + alpha-interferon? Mitomycin C? Gemcitabine? PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona 6.5

Bladder cases #4 71 2000 - gross hematuria, smoker, TURBT 1-2 / Ta BCG x 2years, Oncovite x 4 years no recurrence LFTs abnormal 2004 Ampulla of Vater tumor, Whipple, Miami Bladder cases #4 75-2005 recurrent tumor, 1 / Ta LFTs are normal, NED surgery 78-2008 recurrent tumor, 2 / T1 Grade 2, T1 6.6 PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona

Bladder cases #4 78-2008 recurrent tumor, 2 / T1 instillational ChRx,? restart BCG,? induction, maintenance Oncovite? Bladder cases #5 68 - gross hematuria cystoscopy bladder negative diverticulum, tumor co-morbidities Hpt, DM II, overweight, diverticulitis TURBT; diverticular tumor, 2/T1 bladder mapping, negative PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona 6.7

Bladder cases #5 bladder mapping negative Where do we take biopsies? How many? Technique? what about prostatic urethra? WHERE? Bladder cases #5 distal prostatic urethra WHY? ductal invasion? stromal invasion? stromal invasion has a terrible prognosis! Normal prostatic ducts 6.8 PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona

Prostate Ductal invasion Stromal invasion Prostate Stromal invasion Bladder cases #5 options cystectomy vs partial cystectomy nodes to be done, tumor is on one side, extent LN requirements for partial first tumor cystoscopy, bladder negative bladder mapping negative TCC, grade3, T3 Diverticulum PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona 6.9

Bladder cases #6 62 gross hematuria for 4 months 2 diverticula inferior diverticulum stone superior diverticulum extensive tumor exiting the neck of the diverticulum into the bladder Grade 3, T2 Diverticulum, Bladder muscle wall 6.10 PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona

Muscle Specific Actin Grade 3, T2 Bladder wall Bladder cases #6 62 gross hematuria for 4 months 2 diverticula tumor into the bladder; 2 / T2 not a candidate for partial cyst lymph node dissection extent? Bladder cases #6 62 gross hematuria for 4 months diverticulum tumor but tumor extends into the bladder; 2 / T2 not a candidate for partial cyst lymph node dissection extent more nodes, negative, better? positive nodes, better? proximal nodes positive, distal nodes, IMA, neg, Yes Bladder cases #7 57 year old male coronary artery disease drug-eluting stents, DES, April 2008 Plavix and Aspirin for one year gross hematuria August 2008 cystoscopy and cytology November 2008 single papillary tumor PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona 6.11

Bladder cases #7 What to do? bleeding to death see patient yourself bleeding is 3 RBCs/ hpf What to do? is bleeding to death? how is risk assessed? at 1 month, 3 months, 8 months? Bladder cases #7 What to do? waited for year uneventful TURBT vs TURBT within year; 40% mortality as months progress from DES placerment, mortality from coronary thrombosis lessens. 6.12 PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona

Bladder cases #8 55 - gross hematuria, long history of smoking, cytology positive, TCC PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona 6.13

Bladder cases #8 Grade 3 / T2 55, needs time for business role of neo-adjuvant ChRx, What Chemotherapy? MVAC? MVC? GC? PC? Bladder cases #8 lymph node dissection extent? obturator, hypogastric, external iliac and 2 cm common iliac nodes pre-sacral nodes inter aortic bifurcation nodes nodes pre and para aorta and vena cava to level of Inferior Mesenteric Artery separate node samples Yes, No Bladder cases #8 Grade 3 / T2 cystectomy pto in bladder ileal conduit stage, prostate invasion, No, ChRx? follow-up Remember upper tracts! Cytology? When? Technique? Bladder cases #9 59, bartender former mayor of the town, heavy smoker, saloon owner, acute urinary retention from clots, 6.14 PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona

small cell Bladder cases #9 55, bartender extensive tumor TURBT small cell carcinoma neo-adjuvant ChRx What therapy? transitional cell therapy or small cell therapy? Bladder cases #9 55, bartender neo-adjuvant small cell ChRx cis-platinum and VP 16 complete response radical cystectomy, ileal conduit pathology pto ; follow-up? PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona 6.15

Bladder cases #10 64, gross hematuria Grade 3 / T2 terrible candidate for surgery 350 pounds, CABG x 6, 3 packs a day and refuses to quit or even lessen smoking TCC,Grade3,T2 TCC,Grade3,T2 6.16 PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona

Bladder cases #10 64, gross hematuria Grade 3 / T2 options repeat TURBT chemotherapy cystectomy bladder preservation ChRx + ChXRT neo-adjuvant ChRx + cystectomy Bladder cases #10 64, gross hematuria Grade 3 / T2 repeat extensive TURBT negative for tumor Patient elected surveillance! PERSPECTIVES IN UROLOGY: POINT- COUNTERPOINT November 5 7, 2009 The Scottsdale Plaza Scottsdale, Arizona 6.17